Visual prosthesis

Blackrock Neurotech Reveals Neuralace™: 10,000+ Channel Next-Gen BCI

Retrieved on: 
Wednesday, November 16, 2022
Neuron, Electrode, Anxiety, Movement, Society, Technology, Diffusion, BCIS, Visual prosthesis, Fissure, BCI, Paralysis, Depression, Neuroscience, Research, Patient, Human, CEO, Inflammation, SALT, Brain, Science, Architecture, Medical imaging

SALT LAKE CITY, Nov. 16, 2022 /PRNewswire/ -- Blackrock Neurotech, a leading brain-computer interface company, revealed its next-generation neural interface, Neuralace™, this week at Society for Neuroscience 2022. The ultra-high channel count, flexible electrode gives an important glimpse into the innovative technology that will fuel the company's future BCIs.

Key Points: 
  • The ultra-high channel count, flexible electrode gives an important glimpse into the innovative technology that will fuel the company's future BCIs.
  • "Neuralace demonstrates our belief in where the science must go in order to unlock the true potential of BCI," said Marcus Gerhardt, co-founder and CEO of Blackrock.
  • Blackrock Neurotech created the world's most sophisticated human BCI and remains the leading platform company for BCI technology.
  • In addition, Blackrock produces advanced platform tools for neuroscience, neural engineering and neuroprosthetics, empowering pioneering research at more than 500 leading institutions worldwide.

Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

Retrieved on: 
Tuesday, August 30, 2022
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Security (finance), COVID-19, Conditional sentence, Medicine, Human, Technology, Vivani, File, Type 2, NASDAQ, Commission, ThinkEquity, Severe cognitive impairment, Second Sight, Orion, Physician, Visual prosthesis, Intention, SEC, Type 2 diabetes, Memorandum, U.S. Securities and Exchange Commission, NPM, Leadership, Company, Population, Argus retinal prosthesis, Annual report, Second, Forward-looking statement, Patient, Financial services, Pharmaceutical industry, Medical device, Nasdaq

In connection with the merger, Second Sight changed its name to Vivani Medical, Inc. (Vivani).

Key Points: 
  • In connection with the merger, Second Sight changed its name to Vivani Medical, Inc. (Vivani).
  • ThinkEquity acted as the financial advisor to Second Sight in connection with the merger.
  • Vivani Medical, Inc., which will soon trade under the Nasdaq ticker VANI, is the combination of Nano Precision Medical, Inc. and Second Sight Medical Products, Inc.
  • Prior to the merger, Nano Precision Medical, Inc. was a privately held biopharmaceutical company developing drug implants which utilize its proprietary NanoPortal drug implant technology.

Second Sight Medical Products Announces Closing of Public Offering

Retrieved on: 
Friday, June 25, 2021
Optical, Health, Medical devices, Medical technology, Science and technology, Technology, Emerging technologies, Medical devices, Eye, Prosthetics, Visual prosthesis, Greenshoe, Second Sight, Prosthesis, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underwriters option to purchase additional shares.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underwriters option to purchase additional shares.
  • The gross proceeds from the offering, including the exercise of the over-allotment option, were $57,500,000, before deducting underwriting discounts, commissions and other offering expenses.
  • The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Second Sight Medical Products Announces Pricing of Public Offering

Retrieved on: 
Wednesday, June 23, 2021
General Health, Optical, Health, Medical devices, Medical technology, Biomedical engineering, Biotechnology, Technology, Prosthetics, Neuroprosthetics, Emerging technologies, Medical devices, Visual prosthesis, Second Sight, Implant, Prosthesis, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses.
  • ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
  • The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Second Sight Medical Products Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, June 22, 2021
Optical, Health, Other Health, Medical devices, Medical technology, Prosthetics, Technology, Biotechnology, Biomedical engineering, Emerging technologies, Medical devices, Visual prosthesis, NASDAQ, Prosthesis, Implant, Second Sight, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering.
  • All of the shares of common stock are to be sold by the Company.
  • The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Second Sight Medical Products Announces Results of its 2021 Annual Meeting

Retrieved on: 
Tuesday, June 1, 2021
Health, Medical devices, Other Health, Medical technology, Articles, Medicine, Emerging technologies, Medical devices, Eye, Prosthetics, Visual prosthesis, Prosthesis, COVID-19 pandemic, Second Sight, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

We are behind in our testing due to a pause in the study for the COVID-19 pandemic.

Key Points: 
  • We are behind in our testing due to a pause in the study for the COVID-19 pandemic.
  • We are finishing up our planned two-year testing with encouraging results.
  • The testing done shows that performance is good and stable over the duration of the study.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Second Sight Medical Products Announces Year Three NIH Funding of Its Orion Study

Retrieved on: 
Thursday, May 13, 2021
Research, Optical, Medical devices, Hospitals, University, Education, Clinical trials, Science, Nursing, Medical Supplies, Practice Management, Health, Spacecraft, Emerging technologies, Medical devices, Prosthetics, Spaceflight, Eye, Visual prosthesis, Technology, Orion, College of Medicine, Baylor University, University of California, Los Angeles, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial.

Key Points: 
  • The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial.
  • This NIH notice of grant award follows the reporting by the Company of promising two-year data from the Orion Trial on May 12, 2021.
  • A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston.
  • No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Second Sight Medical Products Announces Two-Year Results of its Orion Study

Retrieved on: 
Wednesday, May 12, 2021
Optical, Health, Clinical trials, Medical devices, Medical technology, Biomedical engineering, Biotechnology, Biological engineering, Prosthetics, Neuroprosthetics, Emerging technologies, Medical devices, Visual prosthesis, Artificial vision, Implant, Prosthesis, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

b'Second Sight Medical Products, Inc. (NASDAQ: EYES) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cSecond Sight\xe2\x80\x9d), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced two-year results of its Early Feasibility Study (Study) of the Orion Visual Cortical Prosthesis (Orion).

Key Points: 
  • b'Second Sight Medical Products, Inc. (NASDAQ: EYES) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cSecond Sight\xe2\x80\x9d), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced two-year results of its Early Feasibility Study (Study) of the Orion Visual Cortical Prosthesis (Orion).
  • The Study is a single arm six subject study at UCLA and Baylor College of Medicine.
  • All subjects are still enrolled in the Study and recent visual function and functional vision results continue to demonstrate that a majority of participants benefit from Orion.
  • No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Pixium Vision receives HealthTech Award for Prima System at the MedTech Forum

Retrieved on: 
Wednesday, April 21, 2021
Ophthalmology, Vision, Branches of biology, Emerging technologies, Macular degeneration, Senescence, Bionics, Retina, Photovoltaic retinal prosthesis, Visual prosthesis

\xe2\x80\x9cThe Prima System has demonstrated its potential to make a significant improvement to the quality of life of patients with dry AMD and this award recognizes its capacity to improve vision.

Key Points: 
  • \xe2\x80\x9cThe Prima System has demonstrated its potential to make a significant improvement to the quality of life of patients with dry AMD and this award recognizes its capacity to improve vision.
  • This study has also demonstrated that patients could simultaneously use prosthetic central vision generated with the Prima System and their remaining peripheral vision, an important step forward in treatment for dry AMD.\nPixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
  • Pixium Vision\xe2\x80\x99s bionic vision systems are associated with a surgical intervention and a rehabilitation period.
  • Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD).

Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors

Retrieved on: 
Tuesday, April 6, 2021
Medical devices, Health, Professional services, Optical, Human resources, Medical technology, Life sciences, Biological engineering, Biomedical engineering, Prosthetics, Neuroprosthetics, Emerging technologies, Visual prosthesis, Bionics, Second Sight, Prosthesis, Implant

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the Company or Second Sight), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Companys Board of Directors has appointed two new members, Dr. Dean Baker and Ms. Alexandra Larson.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (the Company or Second Sight), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Companys Board of Directors has appointed two new members, Dr. Dean Baker and Ms. Alexandra Larson.
  • Dr. Baker serves on the Board of Directors of Nano Precision Medical and served on the Board of Directors of Advanced Bionics prior to its sale to Boston Scientific.
  • He currently serves on the Board of Directors for Transonic Imaging, a medical imaging startup.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.